John Trizzino appointed Immunovaccine CEO
This article was originally published in Scrip
Immunovaccine, a vaccine development company, has appointed John Trizzino chief executive officer, effective 1 October 2011. He joins the company from Novavax where he served as senior vice-president. While there, he successfully negotiated profitable joint venture and licensing agreements, including a $179 million contract with the US government to produce influenza vaccines.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.